Avalo Therapeutics starts Phase 3 in 2027, cash runway extends to 2029
Avalo Therapeutics reports 2026 Q2 financials with $472.2M cash and initiates a Phase 3 HS program in 2027, driving significant investor interest in its long-acting IL-1beta pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day